Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Electric and Physiological Markers, Underlying Mechanisms and Modulation of Cognitive Functioning and Therapeutic Improvement in Response to tACS/CBTp (Transcranial Alternating Current Stimulation Applied at the Beginning of the Cognitive Behavioral Therapy for Psychosis Session) in Combination With the Usual Pharmacological Treatment in Schizophrenia

NCT06889025 is registered in ClinicalTrials.gov with Felicia Iftene as lead sponsor.

NCT NCT06889025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06889025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Electric and Physiological Markers, Underlying Mechanisms and Modulation of Cognitive Functioning and Therapeutic Improvement in Response to tACS/CBTp (Transcranial Alternating Current Stimulation Applied at the Beginning of the Cognitive Behavioral Therapy for Psychosis Session) in Combination With the Usual Pharmacological Treatment in Schizophrenia
Lead sponsor
Felicia Iftene
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 24, 2025
Completion date
June 1, 2027
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia